MarginsXMarginsX
Home › Markets › Health Care › SEPN

Septerna Inc. (SEPN)

SEPN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$41.67
-2.18% on the day
Market cap
$2.0B
Small cap
Revenue · 2025
$46.0M
+4174.5% on 2024
Net income · 2025
-$48.9M
-106.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/0001193125-26-098507-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSEPN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001984086
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$46.0M
Net income-$48.9M
Operating income-$68.3M
Net margin-106.4%
Operating margin-148.6%
Revenue growth+4174.5%
Cash$120.7M
Total assets$596.2M
P/E (computed)Net income was not positive
P/S (computed)43.1×

Warning signs

Cash runway
26.2 months
$167.1M cash at September 30, 2026
Share count, 1 year
+6.2%
2025-11-04 to 2026-11-04
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$44.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$167.1M cash; operating cash flow -$19.1M a quarter.Report 2026-09-30
Shares outstanding47,549,223 (2026-11-04); 44,774,192 a year earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $44.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$18.9M-$26.6M-$13.8M$167.1MNo debt tags$96.3M10-Q 2026-11-09
Q2 2026
2026-06-30
$26.7M-$13.0M-$22.2M$84.7MNo debt tags$98.9M10-Q 2026-08-10
Q1 2026
2026-03-31
$26.5M-$8.6M-$25.6M$71.6MNo debt tags$72.3M10-Q 2026-05-11
Q4 2025
2025-12-31
$24.1M-$10.7M-$15.0M$120.7MNo debt tags$46.0M10-K 2026-03-09
Q3 2025
2025-09-30
$21.5M$8.2M$168.8M$320.0MNo debt tags$22.0M10-Q 2026-11-09
Q2 2025
2025-06-30
$119K-$24.8M-$20.3M$189.3MNo debt tags$726K10-Q 2026-08-10
Q1 2025
2025-03-31
$219K-$21.5M-$23.3M$210.0MNo debt tags$977K10-Q 2026-05-11
Q4 2024
2024-12-31
$212K-$20.7M-$21.0M$238.2MNo debt tags$1.1M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-03-10
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 179 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-12.8%
1 month+17.0%
3 months-5.6%
Year to date+52.8%
1 year+121.4%
From 52-week high-18.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B
MRVIMaravai LifeSciences Holdings Inc.$7.40-1.86%$1.9B
SDGRSchrodinger Inc.$27.36-7.35%$2.1B
TRVITrevi Therapeutics Inc.$13.29-2.64%$1.9B
ZBIOZenas BioPharma Inc.$27.93-0.29%$1.9B
AUPHAurinia Pharmaceuticals Inc$15.48-1.59%$2.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier